Table 1 Baseline characteristics according to the time-to-first cystoscopy from the initial transurethral resection of bladder tumor.

From: Optimal timing for the first cystoscopic follow-up using time-to-treatment initiation analysis of oncologic outcomes in primary non-muscle invasive bladder cancer

Variable

Total (n = 26,660)

Time-to-treatment initiation

p-value

0–2 mo (n = 2402)

2–4 mo (n = 16,880)

4–6 mo (n = 4916)

6–8 mo (n = 1595)

8–12 mo (n = 867)

Sex, n (%)

0.006

 Male

21,653 (81.2%)

1889 (78.6%)

13,775 (81.6%)

4007 (81.5%)

1273 (79.8%)

709 (81.8%)

 

 Female

5007 (18.8%)

513 (21.4%)

3105 (18.4%)

909 (18.5%)

322 (20.2%)

158 (18.2%)

 

Age group at the NMIBC diagnosis year, n (%)

 < 0.001

 < 55

5107 (19.2%)

483 (20.1%)

3297 (19.5%)

826 (16.8%)

350 (21.9%)

151 (17.4%)

 

 55–64

6666 (25.0%)

633 (26.4%)

4253 (25.2%)

1190 (24.2%)

414 (26.0%)

176 (20.3%)

 

 65–74

8742 (32.8%)

761 (31.7%)

5510 (32.6%)

1724 (35.1%)

479 (30.0%)

268 (30.9%)

 

 ≥ 75

6145 (23.0%)

525 (21.9%)

3820 (22.6%)

1176 (23.9%)

352 (22.1%)

272 (31.4%)

 

NMIBC diagnosis year, n (%)

 < 0.001

 2004–2008

7781 (29.2%)

925 (38.5%)

4847 (28.7%)

1242 (25.3%)

478 (30.0%)

289 (33.3%)

 

 2009–2012

8447 (31.7%)

800 (33.3%)

5447 (32.3%)

1515 (30.8%)

423 (26.5%)

262 (30.2%)

 

 2013–2016

10,432 (39.1%)

677 (28.2%)

6586 (39.0%)

2159 (43.9%)

694 (43.5%)

316 (36.4%)

 

Charlson comorbidity index score, n (%)

8394 (31.5%)

830 (34.6%)

5322 (31.5%)

1468 (29.9%)

507 (31.8%)

267 (30.8%)

0.004

 0–1

8343 (31.3%)

735 (30.6%)

5319 (31.5%)

1528 (31.1%)

499 (31.3%)

262 (30.2%)

 

 2–3

9923 (37.2%)

837 (34.8%)

6239 (37.0%)

1920 (39.1%)

589 (36.9%)

338 (39.0%)

 

 ≥ 4

4567 (17.1%)

368 (15.3%)

3003 (17.8%)

795 (16.2%)

261 (16.4%)

140 (16.1%)

 

Repeated TUR-BT, n (%)

2074 (7.8%)

426 (17.7%)

620 (3.7%)

872 (17.7%)

123 (7.7%)

33 (3.8%)

 < 0.001

BCG usage, n (%)

11,662 (43.7%)

788 (32.8%)

7980 (47.3%)

2327 (42.3%)

349 (21.9%)

218 (25.1%)

 < 0.001

UTUC occurrence before the NMIBC diagnosis, n (%)

1128 (4.2%)

84 (3.5%)

731 (4.3%)

202 (4.1%)

73 (4.6%)

38 (4.4%)

0.366

  1. NMIBC non-muscle invasive bladder cancer, TUR-BT transurethral resection of bladder tumor, BCG Bacillus Calmette-Guérin, UTUC upper urinary tract urothelial carcinoma, mo months.
Back to article page